Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD’s pipeline includes Phase 3 candidates for DR ...
Hosted on MSN3mon
Kodiak stock rallies 32% after Jefferies upgrades to buyShares of Kodiak Sciences (NASDAQ:KOD) rallied 32% Monday after Jefferies ... with such upcoming catalysts as Phase 1b data for its drug KSI-101 in the treatment of macular edema secondary to ...
Hosted on MSN2mon
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024The drug and biotech sector had a turbulent year ... Monopar Therapeutics MNPR and Kodiak Sciences KOD, which provided more than double returns in 2024. These stocks also have room for further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback